^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    itraconazole

    Company:
    Generic mfg.
    Drug class:
    CYP51A1 inhibitor
    Related drugs:
    2d
    Histoplasmosis Induction and Consolidation Therapy Factorial Randomized Clinical Trial (Histo-FACT) (clinicaltrials.gov)
    P3, N=664, Not yet recruiting, University of Minnesota
    New P3 trial
    |
    itraconazole • Noxafil (posaconazole)
    6d
    Inhibition of Cholesterol Transport from Lysosomes by Itraconazole Repolarizes Tumor-associated Macrophages to Anti-tumor M1 type. (PubMed, Anticancer Res)
    Inhibition of lysosomal cholesterol release by ITZ reprogrammed M2 macrophages into an M1-like phenotype, revealing a novel mechanism that may serve as a foundation for developing innovative TAM-targeted immunotherapies.
    Journal • IO biomarker
    |
    CD163 (CD163 Molecule) • IL1B (Interleukin 1, beta)
    |
    itraconazole
    7d
    A Study to Learn About How the Study Medicines Called Itraconazole and Probenecid Change How the Body Processes PF-07220060 (clinicaltrials.gov)
    P1, N=28, Recruiting, Pfizer | Not yet recruiting --> Recruiting
    Enrollment open
    |
    itraconazole • atirmociclib (PF-07220060)
    9d
    A Study to Assess the Effect of Itraconazole, Rifampin, and Acid-Reducing Agents on INCB161734 Pharmacokinetics When Administered Orally in Healthy Participants (clinicaltrials.gov)
    P1, N=63, Completed, Incyte Corporation | Recruiting --> Completed
    Trial completion
    |
    itraconazole • rifampicin
    14d
    DB-1311-O-1001: A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors (clinicaltrials.gov)
    P1/2, N=862, Recruiting, DualityBio Inc. | Trial completion date: Jan 2028 --> May 2028 | Trial primary completion date: Sep 2027 --> Dec 2027
    Trial completion date • Trial primary completion date • First-in-human
    |
    EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2) • CD276 (CD276 Molecule)
    |
    BRAF V600E • KRAS mutation • EGFR mutation • KRAS G12C • BRAF V600 • ALK rearrangement • MET exon 14 mutation • ROS1 rearrangement • MET mutation • RET rearrangement • KRAS G12
    |
    Xtandi (enzalutamide) • abiraterone acetate • itraconazole • BNT324 • ritonavir
    14d
    Study to Evaluate the Pharmacokinetics and Safety Effects Following Coadministration of Carbamazepine or Itraconazole With Radiprodil in Healthy Adults (clinicaltrials.gov)
    P1, N=30, Terminated, GRIN Therapeutics, Inc. | Recruiting --> Terminated; Study was terminated due to the lack of operational capabilities of the sites to segregate participants as needed.
    Trial termination
    |
    itraconazole
    14d
    Efficacy of Ultraviolet B Phototherapy in the Management of Resistant and Relapsing Tinea Corporis and Tinea Cruris (clinicaltrials.gov)
    P=N/A, N=36, Not yet recruiting, Cairo University
    New trial
    |
    itraconazole
    14d
    A Study to Evaluate the Effect of Itraconazole and Rifampin on the Drug Levels of AR-LDD (BMS-986365) in Healthy Adult Male Participants (clinicaltrials.gov)
    P1, N=42, Not yet recruiting, Celgene
    New P1 trial
    |
    itraconazole • rifampicin
    18d
    A Trial of Itraconazole Effect on HRS-8080 Pharmacokinetics in Healthy Participants (clinicaltrials.gov)
    P1, N=16, Not yet recruiting, Shandong Suncadia Medicine Co., Ltd.
    New P1 trial
    |
    itraconazole
    21d
    C2321001: A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma (clinicaltrials.gov)
    P1, N=433, Recruiting, Pfizer | Trial completion date: Mar 2026 --> Mar 2029 | Trial primary completion date: Mar 2026 --> May 2028
    Trial completion date • Trial primary completion date
    |
    Xtandi (enzalutamide) • itraconazole • mevrometostat (PF-06821497)
    22d
    Drug-Drug Interaction Study of Casdatifan in Healthy Adult Participants (ARC-29) (clinicaltrials.gov)
    P1, N=14, Completed, Arcus Biosciences, Inc. | Active, not recruiting --> Completed
    Trial completion
    |
    itraconazole • casdatifan (AB521)
    25d
    Effect of Phenytoin or Itraconazole on How BGB-16673 is Absorbed and Removed From the Body in Healthy Participants (clinicaltrials.gov)
    P1, N=37, Completed, BeiGene | Recruiting --> Completed
    Trial completion
    |
    itraconazole • catadegbrutinib (BGB-16673)